-
$4,995 Read More Breast Cancer Therapeutics in Major Developed Markets to 2021 – Growth Driven by Rapid Uptake of Premium Priced Biologics and Ris[...]
Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but th... -
$4,995 Read More Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – Innovative and Diversified Pipeline to Drive Market Gr[...]
Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out es... -
$4,995 Read More Prostate Cancer Market to 2021 – Increasing Disease Prevalence to be a Key Driver of Market Growth
Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors fo... -
$4,995 Read More COPD Therapeutics in Major Developed Markets to 2021 – Emergence of Addition-in-Class and First-in-Class Products Offsets Sales E[...]
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause ... -
$6,995 Read More Frontier Pharma: Versatile Innovation in Oncology – Identifying and Commercializing Versatile First-in-Class Innovation
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and pres... -
$4,995 Read More Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Continued Success of Velcade,[...]
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represen... -
$6,995 Read More Frontier Pharma: Obesity – Identifying and Commercializing First-in-Class Innovation
Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing ... -
$4,995 Read More Hepatitis B Therapeutics in Major Developed Markets to 2021 – Increasing Number of Migrants from High-Prevalence Regions to Drive[...]
Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a signi... -
$4,995 Read More Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 – Emergence of Immunotherapies Drives Market Growth an[...]
Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a... -
$6,995 Read More Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature o...
Sorry, there is no ad related to this category!
-
$4,995 Read More Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 –...
Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a […]
-
$2,000 Read More Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H1 2016
Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H1 2016’, provides an […]
-
$2,000 Read More Constipation – Pipeline Review, H1 2016
Global Markets Direct’s, ‘Constipation – Pipeline Review, H1 2016’, provides an overview of the Constipation […]
-
$2,500 Read More Bacteriuria Global Clinical Trials Review, H1, 2016
This report provides top line data relating to the clinical trials on Bacteriuria. Report includes […]
-
$4,700 Read More Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nu...
Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments […]
-
$1,995 Read More Country Focus: Healthcare, Regulatory and Reimbursement Landscape – China
GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement […]
-
$2,000 Read More Iron Deficiency Anemia – Pipeline Review, H1 2016
Global Markets Direct’s, ‘Iron Deficiency Anemia – Pipeline Review, H1 2016’, provides an overview of […]
-
$2,000 Read More Epstein-Barr Viral Infections – Pipeline Review, H1 2016
Global Markets Direct’s, ‘Epstein-Barr Viral Infections – Pipeline Review, H1 2016’, provides an overview of […]
-
$6,995 Read More Frontier Pharma: Ovarian Cancer – Identifying and Commercializing First-in...
Ovarian cancer is the sixth most common cancer in females and it also has the […]
-
$6,995 Read More Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Aroun...
The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in […]